title: Managing type 2 diabetes: balancing HbA1c and body weight.
abstract: Most patients with type 2 diabetes present with comorbid overweight or obesity. Reaching and maintaining acceptable glycemic control is more difficult in overweight and obese patients, and these conditions are associated with increased risk for cardiovascular and other diseases. Glycemic management for these patients is complicated by the fact that insulin and many of the oral medications available to treat type 2 diabetes produce additional weight gain. However, an increasing number of therapeutic options are available that are weight neutral or lead to weight loss in addition to their glycemic benefits. This article evaluates the evidence from clinical trials regarding the relative glycemic benefits, measured in terms of glycated hemoglobin change, versus the impact on body weight of each medication currently approved for type 2 diabetes. In general, the sulfonylureas, thiazolidinediones, and D-phenylalanine derivatives have been shown to promote weight gain. The dipeptidyl peptidase-4 inhibitors are weight neutral, while the biguanides, incretin mimetics, and amylin mimetics promote weight loss. Trials examining the glycemic benefits of the weight loss agents orlistat and sibutramine are also examined. Awareness of this evidence base can be used to inform medication selection in support of weight management goals for patients with type 2 diabetes.
authors.affiliation: Division of Endocrinology, Diabetes and Metabolism, University of California San Diego, San Diego, CA 92103, USA.
authors.forename: Annie A
authors.initials: AA
authors.lastname: Mavian
authors.forename: Stephan
authors.initials: S
authors.lastname: Miller
authors.forename: Robert R
authors.initials: RR
authors.lastname: Henry
mesh_terms: D019440:Anti-Obesity Agents / Q000627:therapeutic use; D001835:Body Weight / Q000187:drug effects* / Q000502:physiology; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006442:Glycated Hemoglobin / Q000378:metabolism*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D054795:Incretins / Q000502:physiology; D009765:Obesity / Q000150:complications
chemical_list: D019440:Anti-Obesity Agents; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D054795:Incretins